Respiratory and inflammatory diseases constitute a heavy burden for both the individuals affected and for society. AstraZeneca and the Sahlgrenska Academy are now entering into a collaboration in which a guest professorship has been created to reinforce research and drug development in several globally widespread and common diseases.
Respiratory, inflammatory and autoimmune diseases are focus areas given high priority within AstraZeneca’s research. The global pharmaceuticals company is currently conducting several advanced projects in the field, and is leading development in the hunt for new, effective and safe drugs.
Respiratory and inflammatory diseases are also a focus for research carried out at the Sahlgrenska Academy. With a close collaboration between the Academy, the University of Gothenburg, the Sahlgrenska University Hospital and the Västra Götaland Region, plus a number of independent clinics, the Gothenburg region have reached a unique position, in which fundamental laboratory research is directly coupled with day-to-day patient care.
Read the full article at the Sahlgrenska Academy website.